ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2197

Mechanisms of Fetal Growth Restriction in Rheumatologic Autoimmune Diseases: Insights into Placental Pathology and Immune Dysregulation

Larabe Farrukh1, Ananya Venkatesh2, Mana Parast2 and Chelsey Smith3, 1University of California San Diego, San Diego, CA, 2University of California San Diego, San Diego, 3University of California San Diego, LA JOLLA, CA

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, pregnancy, rheumatoid arthritis, Systemic lupus erythematosus (SLE), Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2195–2226) Reproductive Issues in Rheumatic Disorders Posters

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Fetal growth restriction (FGR) significantly contributes to adverse pregnancy outcomes (APOs) in women with rheumatologic diseases. Understanding the immunopathologic mechanisms underlying FGR is critical for risk stratification and management. The objective of this study is to systematically review the immunologic/vascular mechanisms underlying FGR in systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), systemic sclerosis (SSc), ANCA-associated vasculitis (AAV), and seronegative spondyloarthropathies (SpA), and to characterize mechanistic pathways linking autoimmunity to FGR.

Methods: We conducted a systematic search of PubMed and Google Scholar for studies published between 1995 and 2024 that evaluated placental pathology, immune dysregulation, and pregnancy outcomes in women with rheumatologic diseases. Eligible studies included prospective cohorts, retrospective analyses, and placental histopathology investigations. Findings were synthesized narratively due to the heterogeneity of mechanisms.

Results: In SLE and APS, abnormal complement activation, impaired angiogenic signaling, and trophoblast dysfunction contribute to placental insufficiency and FGR. Elevated levels of complement activation products (Bb, sC5b-9) throughout gestation were associated with APOs. In APS, anti-phospholipid antibodies induce trophoblast apoptosis, impair spiral artery remodeling, promote thrombosis, and placental infarction. In RA, cytokine dysregulation, including elevated IL-6 and TNF-α levels and decreased IL-10, were linked to decidual vasculopathy and reduced pro-angiogenic signaling, contributing to low birth weight and preterm birth. In AAV, injury to the syncytiotrophoblasts and endothelial cells of the spiral veins can lead to chorangiosis and focal placental infarction associated with FGR and pre-eclampsia. In SSc, extensive decidual vasculopathy, stromal fibrosis, and hypoperfusion of chorionic villi led to high rates of FGR, preterm birth, and stillbirth. In SpA, elevated rates of preterm birth and cesarean delivery were observed, with limited but suggestive evidence of inflammatory placental lesions. Across diseases, impaired trophoblast function, vascular remodeling, and angiogenic imbalance emerged as overlapping mechanisms of placental insufficiency.

Conclusion: Autoimmune rheumatic diseases contribute to fetal growth restriction through diverse pathways involving immune-mediated placental injury and vascular dysfunction. Early identification of at-risk pregnancies and targeted therapeutic interventions addressing these mechanisms may improve neonatal outcomes. Further research is warranted to delineate disease-specific versus shared pathways to guide precision management strategies.


Disclosures: L. Farrukh: None; A. Venkatesh: None; M. Parast: None; C. Smith: AstraZeneca, 1.

To cite this abstract in AMA style:

Farrukh L, Venkatesh A, Parast M, Smith C. Mechanisms of Fetal Growth Restriction in Rheumatologic Autoimmune Diseases: Insights into Placental Pathology and Immune Dysregulation [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/mechanisms-of-fetal-growth-restriction-in-rheumatologic-autoimmune-diseases-insights-into-placental-pathology-and-immune-dysregulation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mechanisms-of-fetal-growth-restriction-in-rheumatologic-autoimmune-diseases-insights-into-placental-pathology-and-immune-dysregulation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology